{
    "nctId": "NCT00788333",
    "briefTitle": "Combination Study of BMS-754807 and Herceptin\u00ae in Patients With Advanced or Metastatic Her-2-positive Breast Cancer",
    "officialTitle": "A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin\u00ae) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "The dose escalation portion will determine the MTD and recommended Phase 2 dose or dose range of BMS-754807 when administered orally on a daily schedule in combination with trastuzumab administered at standard doses IV on a weekly basis",
    "eligibilityCriteria": "For additional information on this trial, please call (910) 558-2913\n\nInclusion Criteria:\n\n* Subjects with locally advanced or metastatic Her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. Prior treatment with other Her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM-1 etc.) is allowed\n* Histologic or cytologic diagnosis of Her-2-positive breast cancer\n* ECOG status 0 - 1\n\nExclusion Criteria:\n\n* Symptomatic brain metastasis\n* Any condition requiring chronic use of steroids\n* Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms\n* History of glucose intolerance\n* Women of child-bearing potential unwilling or unable to use acceptable contraception methods",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}